Cover Image

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redire...

Full description

Saved in:
Bibliographic Details
Main Authors: Rodriguez-Otero, Paula (Author) , Usmani, Saad (Author) , Cohen, Adam D (Author) , van de Donk, Niels W C J (Author) , Leleu, Xavier (Author) , Gállego Pérez-Larraya, Jaime (Author) , Manier, Salomon (Author) , Nooka, Ajay K (Author) , Mateos, Maria Victoria (Author) , Einsele, Hermann (Author) , Minnema, Monique (Author) , Cavo, Michele (Author) , Derman, Benjamin A (Author) , Puig, Noemi (Author) , Gay, Francesca (Author) , Ho, P Joy (Author) , Chng, Wee-Joo (Author) , Kastritis, Efstathios (Author) , Gahrton, Gösta (Author) , Weisel, Katja (Author) , Nagarajan, Chandramouli (Author) , Schjesvold, Fredik (Author) , Mikhael, Joseph (Author) , Costa, Luciano (Author) , Raje, Noopur S (Author) , Zamagni, Elena (Author) , Hájek, Roman (Author) , Weinhold, Niels (Author) , Yong, Kwee (Author) , Ye, Jing Christine (Author) , Sidana, Surbhi (Author) , Merlini, Giampaolo (Author) , Martin, Tom (Author) , Lin, Yi (Author) , Chari, Ajai (Author) , Popat, Rakesh (Author) , Kaufman, Jonathan L (Author)
Format: Article (Journal)
Language:English
Published: May 2024
In: The lancet. Oncology
Year: 2024, Volume: 25, Issue: 5, Pages: e205-e216
ISSN:1474-5488
DOI:10.1016/S1470-2045(24)00043-3
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(24)00043-3
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204524000433
Get full text
Author Notes:Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels WCJ van de Donk, Xavier Leleu, Jaime Gállego Pérez-Larraya, Salomon Manier, Ajay K Nooka, Maria Victoria Mateos, Hermann Einsele, Monique Minnema, Michele Cavo, Benjamin A Derman, Noemi Puig, Francesca Gay, P Joy Ho, Wee-Joo Chng, Efstathios Kastritis, Gösta Gahrton, Katja Weisel, Chandramouli Nagarajan, Fredik Schjesvold, Joseph Mikhael, Luciano Costa, Noopur S Raje, Elena Zamagni, Roman Hájek, Niels Weinhold, Kwee Yong, Jing Christine Ye, Surbhi Sidana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L Kaufman, on behalf of the International Myeloma Working Group
Description
Summary:Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world. Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The International Myeloma Working Group is also involved in the collection of prospective real-time data of patients treated with such immunotherapies, with the aim of learning continuously and adapting clinical practices to optimise the management of patients receiving immunotherapies.
Item Description:Online verfügbar: 29. April 2024
Gesehen am 06.08.2025
Physical Description:Online Resource
ISSN:1474-5488
DOI:10.1016/S1470-2045(24)00043-3

Similar Items